A Phase 2 interventional study of BYL719 and INC280 in Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Adenocarcinoma of Lung by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Adenocarcinoma of Lung · Novartis.
Among the 16 studies in Adenocarcinoma of Lung by Novartis, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2015, is one of 9 in phase 2, and was the 7th registered.
418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.
Browse Adenocarcinoma of Lung studies →1 of the 16 studies in Adenocarcinoma of Lung by Novartis is open now, in 1 country. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
By country, each count listing its studies:
Of the 58 Adenocarcinoma of Lung studies recruiting now, 36 (62%) set no upper age limit and 10 (17%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 60 across 293 interventional studies indexed under Adenocarcinoma of Lung.
Median enrollment 124 across the 13 interventional studies, 44 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Adenocarcinoma of Lung by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162 in advanced NSCLC patients carrying specific molecular alterations.
There is a great unmet medical need in NSCLC patients with advanced or metastatic disease. Novel approaches using targeted therapeutic agents for these patient populations with molecular characterization could potentially identify subsets of advanced NSCLC patients who would benefit from targeted kinase inhibition. Study treatments, BYL719, INC280, LDK378 and MEK162, which target PIK3CA, c-MET, ALK/ROS1 and MEK respectively, have shown promising data in either preclinical or clinical lung cancer settings.
To enter the screening phase of the study, the subjects' molecular alterations were determined using locally validated methodologies from a newly obtained tumor sample (preferred) or the most recent archival tumor sample available. Based on the molecular alterations of the tumor, subjects were assigned to one of the treatment arms. Subjects with multiple molecular alterations in epidermal growth factor receptor (EGFR) and the relevant pathways were excluded, except under the conditions described in Inclusion criteria.
The treatment period began on Cycle 1 Day 1 and continued in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of informed consent, death or the subject transferred to another Novartis study that could continue to provide the study drug.
All subjects were required to be followed up for 30 days for safety after receiving the last dose of study treatment. Subjects who discontinued study treatment for any reason other than disease progression were followed up for progression of disease. All subjects were required to be followed for survival. For subjects transferred to another Novartis study, an end of treatment visit (EOT) was required to be performed and the subject would not enter the follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient's tumor must have molecular alteration of the PIK3CA gene.
Drug: BYL719
Patient's tumor must have molecular alteration of the c-MET gene.
Drug: INC280
Patient's tumor must have ALK or ROS1 gene rearrangement.
Drug: LDK378
Patient's tumor must have KRAS, NRAS or BRAF mutation.
Drug: MEK162
BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
Overall Response Rate (ORR)
Overall response rate is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (Overall Response (OR) = CR + PR). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to 231 weeks
Median Overall Survival (OS)
OS is defined as the time from date of randomization/start of treatment to date of death due to any cause.
Time frame: Up to 231 weeks
Number of Participants With Progression-free Survival (PFS)
PFS event is defined as the first documented progression or death due to any cause according to RECIST 1.1 criteria
Time frame: Up to 231 weeks
Disease Control Rate (DCR)
DCR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR) or Stable Disease (SD) according to RECIST 1.1 criteria (DCR: CR+PR+SD) Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD
Time frame: Up to 231 weeks
Median Duration of Overall Response (DOR)
Duration of overall response (DOR) is defined as the time from the first documented CR or PR (confirmed by the subsequent assessment) to the date of the first documented progression or death due to underlying cancer.
Time frame: Up to 231 weeks
Number of Participants With Adverse Events
Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life-threatening, corresponding to grades 1 - 4, was used.
Time frame: up to 235 weeks
Pharmacokinetics Profile, AUCtau and AUClast
PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). AUCtau is the AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1) AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)
Pharmacokinetics Profile, Cmax
PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Cmax is the maximum (peak) observed plasma concentration (mass x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)
Pharmacokinetics Profile, Tmax
PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Tmax is the time to reach maximum (peak) plasma concentration (time) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours) and Day 15 (pre dose, 0.5, 1, 2, 4, 6, 8 hours post dose and only for BYL719 350 mg QD and LDK378 750 mg QD arms also at 24 hours post dose)
Participants were from China
| Milestone | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Started | 2 | 16 | 26 | 22 |
| Completed | 0 | 0 | 6 | 0 |
| Not completed | 2 | 16 | 20 | 22 |
| Withdrew: Death | 1 | 0 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 1 | 13 | 12 | 14 |
| Withdrew: Subject/guardian decision | 0 | 1 | 0 | 3 |
| Withdrew: Adverse event | 0 | 2 | 8 | 2 |
Overall response rate is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (Overall Response (OR) = CR + PR). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
| Participants | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Overall Response Rate (ORR) | 0 | 3 | 19 | 2 |
OS is defined as the time from date of randomization/start of treatment to date of death due to any cause.
| Months | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Median Overall Survival (OS) | 4.99 (0.30 to 9.69) | 13.26 (1.18 to 23.33) | NA (19.35 to NA) | 9.20 (3.52 to 11.93) |
PFS event is defined as the first documented progression or death due to any cause according to RECIST 1.1 criteria
| Participants | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Number of Participants With Progression-free Survival (PFS) | 2 | 16 | 19 | 19 |
DCR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR) or Stable Disease (SD) according to RECIST 1.1 criteria (DCR: CR+PR+SD) Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD
| Percentage of participants | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Disease Control Rate (DCR) | 50.0 (1.3 to 98.7) | 43.8 (19.8 to 70.1) | 92.3 (74.9 to 99.1) | 59.1 (36.4 to 79.3) |
Duration of overall response (DOR) is defined as the time from the first documented CR or PR (confirmed by the subsequent assessment) to the date of the first documented progression or death due to underlying cancer.
| Months | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Median Duration of Overall Response (DOR) | — | 3.84 (3.81 to 5.59) | 34.96 (7.59 to NA) | 5.47 (3.55 to 7.39) |
Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life-threatening, corresponding to grades 1 - 4, was used.
| Participants | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| AE All grades | 2 | 16 | 26 | 22 |
| AE Grade 3/4 | 1 | 11 | 23 | 20 |
| SAE All grades | 1 | 12 | 11 | 18 |
| SAE Grade 3/4 | 1 | 7 | 9 | 15 |
PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). AUCtau is the AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1) AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed
| ng*h/mL | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| AUClast Cycle 1 Day 1 | 20909 ± 107 | — | — | — |
| AUCtau Cycle 1 Day 15 | 23892 ± NA | 32034 ± 6992 | 30361 ± 3807 | 2645 ± 981 |
| AUClast Cycle 1 Day 15 | 23721 ± NA | 27875 ± 7629 | 28013 ± 5006 | 2642 ± 1026 |
PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Cmax is the maximum (peak) observed plasma concentration (mass x volume-1) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed
| ng/mL | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Cmax Cycle 1 Day 1 | 2135 ± 700 | — | — | — |
| Cmax Cycle 1 Day 15 | 2630 ± NA | 8046 ± 3550 | 1362 ± 177 | 587 ± 183 |
PK parameters are estimated from each individual plasma concentration-time profile using non-compartmental analysis (Phoenix software version 6.2 and above). Tmax is the time to reach maximum (peak) plasma concentration (time) On Cycle 1 Day 1, PK parameters for only BYL719 350 mg QD arm were analyzed
| hours | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| Tmax Cycle 1 Day 1 | 4.03 (2.05 to 6.00) | — | — | — |
| Tmax Cycle 1 Day 15 | 2.00 (2.00 to 2.00) | 1.00 (0.467 to 6.17) | 6.10 (2.03 to 8.00) | 1.10 (0.517 to 7.58) |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days after receiving the last dose of study treatment, up to maximum duration of 235 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYL719 350 mg QD | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| INC280 400 mg BID Tab/600 mg BID Cap | 4/16 (25%) | 12/16 (75%) | 16/16 (100%) |
| LDK378 750 mg QD | 1/26 (3.8%) | 11/26 (42.3%) | 26/26 (100%) |
| MEK162 45 mg BID | 5/22 (22.7%) | 18/22 (81.8%) | 22/22 (100%) |
| Event | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/2 | 5/16 | 1/26 | 4/22 |
| PneumoniaInfections and infestations | 0/2 | 2/16 | 3/26 | 4/22 |
| Blood creatine phosphokinase increasedInvestigations | 0/2 | 0/16 | 0/26 | 4/22 |
| PyrexiaGeneral disorders | 0/2 | 1/16 | 0/26 | 3/22 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/2 | 2/16 | 1/26 | 3/22 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/2 | 0/16 | 2/26 | 0/22 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/2 | 0/16 | 2/26 | 0/22 |
| AstheniaGeneral disorders | 0/2 | 1/16 | 0/26 | 1/22 |
| Non-cardiac chest painGeneral disorders | 0/2 | 1/16 | 0/26 | 0/22 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/2 | 1/16 | 0/26 | 0/22 |
| Event | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/2 | 4/16 | 26/26 | 14/22 |
| Aspartate aminotransferase increasedInvestigations | 1/2 | 5/16 | 26/26 | 16/22 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/2 | 14/16 | 21/26 | 13/22 |
| Alanine aminotransferase increasedInvestigations | 0/2 | 7/16 | 24/26 | 6/22 |
| AnaemiaBlood and lymphatic system disorders | 0/2 | 13/16 | 19/26 | 18/22 |
| Abdominal pain upperGastrointestinal disorders | 0/2 | 2/16 | 20/26 | 3/22 |
| VomitingGastrointestinal disorders | 0/2 | 6/16 | 20/26 | 9/22 |
| Blood creatine phosphokinase increasedInvestigations | 0/2 | 2/16 | 7/26 | 16/22 |
| RashSkin and subcutaneous tissue disorders | 0/2 | 0/16 | 12/26 | 16/22 |
| HyperuricaemiaMetabolism and nutrition disorders | 1/2 | 5/16 | 17/26 | 4/22 |
| Age, Continuous(years) | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 53.0 (44 to 62) | 58.2 (47 to 65) | 49.4 (33 to 66) | 60.3 (48 to 74) | 55.3 (33 to 74) |
| Sex: Female, Male(Participants) | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID | Total |
|---|---|---|---|---|---|
| Female | 0 | 5 | 15 | 3 | 23 |
| Male | 2 | 11 | 11 | 19 | 43 |
| Race and Ethnicity Not Collected(Participants) | BYL719 350 mg QD | INC280 400 mg BID Tab/600 mg BID Cap | LDK378 750 mg QD | MEK162 45 mg BID | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jan 2015 to primary completion in Oct 2019, 56 months.
Results were first posted in Dec 2020, 1 year 2 months after primary completion.
Of 53 phase 2 interventional studies under Adenocarcinoma of Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 56 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alpelisib · Capmatinib · Ceritinib · Binimetinib